Supriya Lifescience names Dr. Saloni Wagh as MD
Shivani Satish Wagh takes on the role of Joint Managing Director
Shivani Satish Wagh takes on the role of Joint Managing Director
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Strong topline growth driven by solid performance across key brands.
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Subscribe To Our Newsletter & Stay Updated